480 related articles for article (PubMed ID: 35400561)
1. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
Kang M; Yi Y; Li Y; Sun L; Deng A; Hu T; Zhang J; Liu J; Cheng M; Xie S; Luo M; Jiang J; Jiang Y; Tang S; He J
Ann Intern Med; 2022 Apr; 175(4):533-540. PubMed ID: 35099990
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.
Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W
Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173
[TBL] [Abstract][Full Text] [Related]
4. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.
Wu D; Zhang Y; Tang L; Wang F; Ye Y; Ma C; Zheng H; Yu W; Cao L; Song Y; Reyimu A; Zhang X; Wang H; Nie Y; Lu M; Qi M; Li J; Wang R; Yang K; Wang C; Rodewald LE; Gao GF; An Z; Yin Z
China CDC Wkly; 2022 Jan; 4(4):57-65. PubMed ID: 35186369
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
[TBL] [Abstract][Full Text] [Related]
10. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
[TBL] [Abstract][Full Text] [Related]
11. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China.
Ma C; Huang C; Wang W; Song Y; Jiang X; Tian X; Liu B; Chi F; Lang S; Liu D; Sun W; Tang L; Wu D; Song Y; Li J; Rodewald L; Yin Z; An Z
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851170
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
Kerr S; Vasileiou E; Robertson C; Sheikh A
J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
16. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
17. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.
Khan UI; Niaz M; Azam I; Hasan Z; Hassan I; Mahmood SF; Ali A
BMJ Open; 2023 Jun; 13(6):e071789. PubMed ID: 37369396
[TBL] [Abstract][Full Text] [Related]
19. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study.
Tang L; Zhang Y; Wang F; Wu D; Qian ZH; Zhang R; Wang AB; Huang C; Wang H; Ye Y; Lu M; Wang C; Ma YT; Pan J; Li YF; Lv XY; An Z; Rodewald L; Wang XY; Shao YM; Wu ZY; Yin Z
BMJ Open; 2022 Nov; 12(11):e063919. PubMed ID: 36368753
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.
Hu Z; Tao B; Li Z; Song Y; Yi C; Li J; Zhu M; Yi Y; Huang P; Wang J
Int J Infect Dis; 2022 Mar; 116():204-209. PubMed ID: 35065255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
